BridgeBio Pharma, Inc.
68.56USD
+0.4400 (+0.65%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on BBIO.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | -$0.56▼ | -$0.45 | 1 | 0 |
| Next quarter | -$0.4▼ | -$0.25 | 0 | 1 |
| Current year | -$2.62▼ | -$2.14 | 0 | 8 |
| Next year | -$0.22▼ | $0.59 | 1 | 0 |
Beat in 1 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | -$0.58 | -$0.78 | -0.20 (-33.9%) |
| 2026-03-31 | -$0.62 | -$0.84 | -0.22 (-36.2%) |
| 2025-12-31 | -$0.62 | -$0.94 | -0.32 (-50.6%) |
| 2025-09-30 | -$0.78 | -$0.72 | +0.06 (+7.7%) |
183 ratings from 31 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Morgan Stanley | Maintained | Overweight | $97 $87 | Oct 21, 2026 |
| Citigroup | Maintained | Neutral | $94 $91 | Oct 19, 2026 |
| Piper Sandler | Maintained | Overweight | $115 $120 | Oct 19, 2026 |
| Barclays | Maintained | Overweight | $157 $156 | Oct 7, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $120 | Sep 10, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $120 | Sep 2, 2026 |
| Mizuho | Maintained | Outperform | $96 $110 | Sep 1, 2026 |
| Truist Securities | Maintained | Buy | $102 $107 | Aug 12, 2026 |
| Canaccord Genuity | Maintained | Buy | $104 $106 | Aug 12, 2026 |
| JP Morgan | Maintained | Overweight | $100 $111 | Aug 12, 2026 |
| B of A Securities | Maintained | Buy | $101 $104 | Aug 11, 2026 |
| TD Cowen | Maintained | Buy | $95 $110 | Aug 11, 2026 |
| Morgan Stanley | Maintained | Overweight | $98 $97 | Aug 11, 2026 |
| Piper Sandler | Maintained | Overweight | $111 $115 | Aug 11, 2026 |
| Wells Fargo | Maintained | Overweight | $98 $102 | Aug 11, 2026 |
| Citigroup | Maintained | Neutral | $82 $93 | Jul 16, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $110 $120 | Jul 13, 2026 |
| Mizuho | Maintained | Outperform | $106 $96 | Jun 16, 2026 |
| Canaccord Genuity | Initiated | Buy | $104 | Jun 3, 2026 |
| Morgan Stanley | Maintained | Overweight | $94 $98 | May 28, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $110 | May 28, 2026 |
| Raymond James | Downgraded from Outperform | Market Perform | — | May 26, 2026 |
| Citigroup | Initiated | Neutral | $82 | May 19, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $100 $110 | May 11, 2026 |
| Evercore ISI Group | Maintained | Outperform | $125 $130 | May 8, 2026 |
141 filings from 20 insiders · 20 buy / 14 sell over 6m
Officers and directors of BBIO, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kumar NeilDirector; Officer, Chief Executive Officer | Sellindirect | 1.3k | $69.57 | $89k | Sep 17, 2026 |
| Kumar NeilDirector; Officer, Chief Executive Officer | Sellindirect | 8.7k | $69.01 | $602k | Sep 17, 2026 |
| KUMAR NEILChief Executive Officer | Sell | 45.0k | $81.15 | $3.73M | Aug 19, 2026 |
| KUMAR NEILChief Executive Officer | Other | 71.2k | — | — | Aug 14, 2026 |
| APULI MARICELOfficer | Sell | 2.0k | $80.06 | $160k | Jul 30, 2026 |
| ELLIS ANDREADirector | Sell | 17.2k | $84.00 | $1.44M | Jul 9, 2026 |
| COOK JENNIFER EDirector | Sell | 148.6k | $84.00 | $13.16M | Jul 9, 2026 |
| ELLIS ANDREADirector | Exercise | 17.2k | $16.75 | $288k | Jul 9, 2026 |
| COOK JENNIFER EDirector | Exercise | 148.6k | $8.45 | $3.71M | Jul 9, 2026 |
| COOK JENNIFER EDirector | Sell | 39.4k | $68.57 | $2.75M | Jun 24, 2026 |
| COOK JENNIFER EDirector | Exercise | 37.2k | $8.45 | $457k | Jun 24, 2026 |
| VALANTINE HANNAH A.Director | Sell | 5.0k | $68.00 | $342k | Jun 23, 2026 |
| VALANTINE HANNAH A.Director | Exercise | 2.8k | $41.73 | $117k | Jun 22, 2026 |
| HOMCY CHARLES JDirector | Grant | 4.0k | — | — | Jun 22, 2026 |
| MCCORMICK FRANK P. PH.D.Director | Grant | 4.0k | — | — | Jun 22, 2026 |
| DANIELS RONALD JDirector | Grant | 4.0k | — | — | Jun 22, 2026 |
| MOMTAZEE JAMES CDirector | Grant | 4.0k | — | — | Jun 22, 2026 |
| SATVAT ALI JDirector | Grant | 4.0k | — | — | Jun 22, 2026 |
| AGUIAR ERICDirector | Grant | 4.0k | — | — | Jun 22, 2026 |
| DACHILLE DOUGLAS A.Director | Grant | 4.0k | — | — | Jun 22, 2026 |
No analyst notes on BBIO yet.
Analyst Ratings
21 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 6 | 15 | 2 | 0 | 0 | Buy1.83 |
| 1 mo ago | 5 | 14 | 3 | 0 | 0 | Buy1.91 |
| 2 mo ago | 5 | 14 | 3 | 0 | 0 | Buy1.91 |
| 3 mo ago | 6 | 14 | 2 | 0 | 0 | Buy1.82 |
Members whose judged calls on BBIO have played out most reliably.
No settled calls on BBIO yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice